{"id":"pyronaridine-artesunate-pa","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL35228","moleculeType":"Small molecule","molecularWeight":"518.06"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pyronaridine is a dihydroorotate dehydrogenase inhibitor, while artesunate is a beta-hematin formation inhibitor. This dual-action mechanism allows for effective treatment of malaria.","oneSentence":"Pyronaridine-artesunate is a combination of pyronaridine and artesunate, which work together to inhibit the growth of malaria parasites.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:44.450Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of uncomplicated Plasmodium falciparum malaria"}]},"trialDetails":[{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":"Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)","enrollment":1510},{"nctId":"NCT05343312","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2022-03-16","conditions":"Malaria","enrollment":870},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT04695197","phase":"PHASE3","title":"Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2021-01-08","conditions":"Covid-19, Malaria","enrollment":143},{"nctId":"NCT01868438","phase":"PHASE1","title":"Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2013-05","conditions":"Malaria","enrollment":60},{"nctId":"NCT00682630","phase":"PHASE1","title":"Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-09","conditions":"Malaria","enrollment":42},{"nctId":"NCT01156389","phase":"PHASE1","title":"Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2010-07","conditions":"Malaria","enrollment":34},{"nctId":"NCT00331136","phase":"PHASE2","title":"Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2006-06","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":60},{"nctId":"NCT00541385","phase":"PHASE3","title":"Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-10","conditions":"Malaria","enrollment":535},{"nctId":"NCT00440999","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-03","conditions":"Malaria","enrollment":456},{"nctId":"NCT00422084","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Malaria","enrollment":1272},{"nctId":"NCT04049916","phase":"PHASE2, PHASE3","title":"Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-09-12","conditions":"Malaria,Falciparum","enrollment":100},{"nctId":"NCT01552330","phase":"PHASE1","title":"Pharmacokinetic Study of Primaquine and Pyronaridine-Artesunate in Healthy Subjects","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-05","conditions":"Healthy","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pyramax"],"phase":"phase_3","status":"active","brandName":"Pyronaridine-artesunate (PA)","genericName":"Pyronaridine-artesunate (PA)","companyName":"Liverpool School of Tropical Medicine","companyId":"liverpool-school-of-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pyronaridine-artesunate is a combination of pyronaridine and artesunate, which work together to inhibit the growth of malaria parasites. Used for Treatment of uncomplicated Plasmodium falciparum malaria.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}